Altimmune Inc (ALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH136550D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

37

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Altimmune Inc (Altimmune), formerly Vaxin Inc is an immunotherapeutics company that develops vaccines and other biological products. The company's products include nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy for patients chronically infected with the hepatitis B virus. Its preclinical stage products include nasoshield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and oncosyn, an immunotherapeutic for treating solid cancer indications. Altimmune's products are used in the treatment of acute respiratory infections, chronic viral infections, and cancer. The company uses respirvec and densigen technologies for the development of vaccines. It has operations in London, UK; and Strasbourg, France. Altimmune is headquartered in Gaithersburg, Maryland, the US.

Altimmune Inc (ALT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Altimmune Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Altimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Altimmune Inc, Medical Devices Deals, 2012 to YTD 2018 9

Altimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Altimmune Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Vaxin Raises USD16 Million in Venture Financing 11

Partnerships 12

Altimmune Enters into Contract Agreement with BARDA for NasoShield 12

Merger 13

Altimmune Merges with PharmAthene in Reverse Merger Transaction 13

Licensing Agreements 15

Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 15

Equity Offering 16

Altimmune to Raise USD25 Million in Private Placement of Units 16

Altimmune Raises USD12 Million in Public Offering of Shares 17

Altimmune Raises USD4.9 Million in Private Placement of Shares 19

Altimmune Raises USD14.7 Million in Private Placement of Series B Preferred Shares 20

Asset Transactions 22

WCCT Acquires Challenge Virus from Immune Targeting Systems 22

Acquisition 23

Vaxin Acquires Immune Targeting Systems 23

Altimmune Inc-Key Competitors 24

Altimmune Inc-Key Employees 25

Altimmune Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Aug 14, 2018: Altimmune announces second quarter 2018 financial results and provides corporate update 27

May 15, 2018: Altimmune Reports First Quarter 2018 Financial Results 28

Mar 28, 2018: Altimmune Reports Financial Results for the Year Ended December 31, 2017 29

Nov 09, 2017: Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update 31

Aug 10, 2017: Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update 33

Corporate Communications 34

Jul 10, 2018: Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds Jose Ochoa to Its Leadership Team as Chief Business Officer 34

Jan 03, 2018: Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors 35

May 16, 2017: Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List of Figure

List of Figures

Altimmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Altimmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Altimmune Inc, Medical Devices Deals, 2012 to YTD 2018 9


List of Table

List of Tables

Altimmune Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Altimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Altimmune Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Altimmune Inc, Medical Devices Deals, 2012 to YTD 2018 9

Altimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Vaxin Raises USD16 Million in Venture Financing 11

Altimmune Enters into Contract Agreement with BARDA for NasoShield 12

Altimmune Merges with PharmAthene in Reverse Merger Transaction 13

Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 15

Altimmune to Raise USD25 Million in Private Placement of Units 16

Altimmune Raises USD12 Million in Public Offering of Shares 17

Altimmune Raises USD4.9 Million in Private Placement of Shares 19

Altimmune Raises USD14.7 Million in Private Placement of Series B Preferred Shares 20

WCCT Acquires Challenge Virus from Immune Targeting Systems 22

Vaxin Acquires Immune Targeting Systems 23

Altimmune Inc, Key Competitors 24

Altimmune Inc, Key Employees 25

Altimmune Inc, Subsidiaries 26

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022